19 February 2026 23:00 UTC · European Commission · EU Commission Press Release · Source · Email X Link

European Commission commits €225 million to next-generation flu vaccines

Key points

€225 million investment to accelerate next-generation influenza vaccines
Pre-commercial procurement funds clinical development through market authorisation (98 months)

TL;DR

EU commits €225 million using pre-commercial procurement to advance clinical development of broader, more adaptive influenza vaccines.
Funding covers clinical phases I–III and pre-market work with contracts running 98 months and aims to speed market access and scale production.
Targets user-friendly administration (nose, mouth, skin patches), supports SMEs, and is financed under the EU4Health programme via the Health Emergency Preparedness and Response Authority and managed by HaDEA.

Original text

European Commission - Press release Commission invests €225 million to deliver next-generation influenza vaccines Brussels, 20 February 2026 The European Union is committing €225 million to speed up the development of next-generation flu vaccines that will offer protection across a wider range of influenza variants and quickly adapted if a pandemic strain emerges. It marks the first time the Commission will be using pre-commercial procurement to advance products through clinical trials, ensuring they meet strict safety, quality and efficacy criteria, while supporting innovations that might otherwise stall without public intervention. The funding will support vaccines designed to be easier to administer via the nose, mouth or skin patches and rapidly scaled up in emergencies. Flu viruses evolve constantly, which means vaccine technology must keep pace. This investment will accelerate vaccine development and strengthen Europe's ability to respond at scale. Through full clinical development of promising vaccine candidates, the EU aims to widen the pipeline, putting more products in development. This increases the chances of novel products making it to the market, and move from laboratory breakthrough to real-world protection. That means new solutions can reach national vaccination programmes more quickly, providing patient friendly vaccines to help countries respond with greater speed and coordination when outbreaks intensify. The contracts signed will run for 98 months, covering clinical development through to market authorisation. By expanding vaccine production capacity and introducing novel treatments, this investment will help Europe and the world to be better prepared for future influenza outbreaks or pandemics. Background This investment uses a pre-commercial procurement model, which funds research and development under favourable terms to foster a more inclusive market, particularly for SMEs. It covers three phases of pre-commercial procurement, including development of clinical trial phases I, II and III, as well as pre-market development, leading to market authorisation. These actions are financed by the Commission's Health Emergency Preparedness and Response Authority from the EU4Health programme, and managed by the European Health and Digital Executive Agency . The contracts have been signed with Nivi Development P/S, Ethris Gmbh, Statens Serum Institut, Vismederi Srl, Stichting European Clinical Research Alliance On Infectious Diseases, Bavarian Nordic As, Evonik Operations Gmbh, Idt Biologika Gmbh, Sanofi Pasteur Sa And Sclavo Vaccines Association. For more information HaDEA press release IP/26/399 Quote(s): "With an EU investment of €225 million - the largest ever dedicated to accelerating access to innovative medical countermeasures - we are advancing the development of next-generation flu vaccines. Innovation is at the heart of preparedness. This funding will unlock cutting-edge technologies, including more accessible and diverse vaccine administration methods, ensuring that effective vaccine options reach underserved and vulnerable groups. This investment also strengthens Europe’s pharmaceutical ecosystem, contributing to its competitiveness, and reinforces our resilience against future health threats." Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management Press contacts: Eva HRNCIROVA (+32 2 29 88433) Quentin CORTES (+32 2 29 13283) General public inquiries: Europe Direct by phone 00 800 67 89 10 11 or by email

Key tags

Topics

Keywords

Stats

Word count: 503

Summary words: 91

Compression: 18%

Boilerplate removed: Yes

Top phrases:

Entities

People

Organizations

Places

Countries

Regions

Europe